BACKGROUND: In this retrospective study, the possibility of using @entity115 / @entity798 for empirical therapy of @entity298 as an alternative to @entity2892 was explored. METHODS: All @entity298 cases at our institution between 1998 and 2000 were included. Susceptibility to @entity2892 and @entity115 / @entity798 of microorganisms isolated in peritoneal fluid and success rates were compared. Therapeutic failure was defined as death, necessity of repeated surgical intervention, or clinical deterioration with persistent positive cultures. RESULTS: Seventy-six cases of @entity298 with 156 microorganisms were found. One hundred and forty-nine (98%) were susceptible to @entity2892 versus 124 (82%) to @entity115 / @entity798 (p = 0.0001). Thirteen therapeutic failures occurred in 52 @entity1 treated with @entity115 / @entity798 (25%) versus 3 out of 8 (38%) with @entity2892 (p = 0.43). The proportion of organisms resistant to @entity115 / @entity798 in therapeutic failures was greater in nosocomial versus community-acquired @entity298 (p = 0.041). CONCLUSION: Despite its better in vitro bacteriological activity, clinical efficacy of @entity2892 was identical to @entity115 / @entity798 . The use of @entity115 / @entity798 instead of @entity2892 would save 889 @entity7634 per case.

Treatment of XXXX : is a less expensive broad-spectrum antibiotic as effective as a carbapenem?

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2892 :: ('MESH:D015378', 'Chemical') :: ['imipenem'] @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin'] @entity798 :: ('MESH:D019818', 'Chemical') :: ['clavulanate'] @entity298 :: ('MESH:D010538', 'Disease') :: ['secondary peritonitis'] @entity7634 :: ('9319', 'Species') :: ['Euro']
@entity298 :: (MESH:D010538,Disease) :: ['secondary peritonitis']
